ReviewCurrent rheumatology reports2019
Clinical Insights into Diffuse Alveolar Hemorrhage in Antiphospholipid Syndrome.
Review in Current rheumatology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Consecutive PRES and diffuse alveolar hemorrhage in a patient with active lupus nephritis and antiphospholipid antibodies: a case report and systematic literature review.BMC nephrology · 2026Pooled it
- Association between antiphospholipid antibodies and diffuse alveolar haemorrhage risk in systemic lupus erythematosus: a systematic review and meta-analysis.Rheumatology (Oxford, England) · 2025Pooled it
- Antiphospholipid antibody-related hepatic vasculitis in a juvenile after non-severe COVID-19: a case report and literature review.Frontiers in immunology · 2024Pooled it
- A 45-Year-Old Man With Dyspnea and Hypoxemia With Bilateral Pulmonary Infiltrates.CHEST pulmonary · 2026Article
- Clinical, radiological and laboratory features and outcomes of diffuse alveolar hemorrhage.Scientific reports · 2026Article
- Diffuse alveolar hemorrhage in rheumatic diseases: Clinical features, diagnosis, and management.Rheumatology and immunology research · 2026Article
- [Clinical characteristics and prognosis of primary immune thrombocytopenia complicated with diffuse alveolar hemorrhage].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- Development of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-A/B Report: Defining and Structuring the Clinical and Laboratory Domains.Current rheumatology reports · 2025Review
- Connective Tissue Disorder-Induced Diffuse Alveolar Hemorrhage: A Comprehensive Review with an Emphasis on Airway and Respiratory Management.Life (Basel, Switzerland) · 2025Review
- Diffuse Alveolar Hemorrhage Associated With Anti-PL-7 Antisynthetase Syndrome: A Case Report.Case reports in pulmonology · 2025Article
- Article
- Should bleeding be a concern in antiphospholipid syndrome?Research and practice in thrombosis and haemostasis · 2024Article
- Article
- Diffuse alveolar haemorrhage as a rare complication of antiphospholipid syndrome.Respirology case reports · 2022Article
- Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria.Arthritis care & research · 2021Review
- Management of Severe Refractory Systemic Lupus Erythematosus: Real-World Experience and Literature Review.Clinical reviews in allergy & immunology · 2021Review
- Management of Non-criteria Manifestations in Antiphospholipid Syndrome.Current rheumatology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDiffuse alveolar hemorrhage (DAH) is a rare but devastating manifestation of antiphospholipid syndrome (APS) patients with or without other systemic autoimmune diseases. Data regarding diagnosis and treatment are limited to case series. We review diagnostic and therapeutic strategies employed in APS patients with DAH and discuss our experience in managing these complex patients. RECENT
findingsPulmonary capillaritis likely contributes to the pathogenesis, however is only observed in half of the biopsies. Corticosteroids induce remission in the majority of patients, however almost half recur and require a steroid-sparing immunosuppressive to maintain remission. Cyclophosphamide- or rituximab-based regimens achieve the highest remission rates (50%); other strategies include intravenous immunoglobulin, plasmapheresis, mycophenolate mofetil, and/or azathioprine. Given the rarity of DAH in APS, treatment is guided by interdisciplinary experience. Why certain patients achieve full remission with corticosteroids while others require immunosuppressive agents is unknown; future research should focus on the pathophysiology and optimal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.